-
公开(公告)号：US07803367B2
公开(公告)日：2010-09-28
申请号：US12316194
申请日：2008-12-10
Applicant: Hua-Lin Wu , Guey-Yueh Shi
Inventor： Hua-Lin Wu , Guey-Yueh Shi
IPC: C12N9/00
CPC classification number: A61K48/00 , A61K38/366
Abstract: The invention relates to a composition for promoting angiogenesis, for controlling DNA synthesis of a cell, and for controlling chemotactic motility of a cell. The invention also relates to a method for treating ischemia diseases.
Abstract translation: 本发明涉及促进血管发生的组合物，用于控制细胞的DNA合成和用于控制细胞的趋化运动性。 本发明还涉及一种治疗缺血性疾病的方法。
-
2.发明申请Compositions, kits and treating methods for alteration cell-cell adhesion, transport, or permeation properties of tissues 失效用于组织改变细胞粘附，转运或渗透性质的组合物，试剂盒和处理方法公开(公告)号：US20050106135A1
公开(公告)日：2005-05-19
申请号：US10938183
申请日：2004-09-10
Applicant: Hua-Lin Wu , Guey-Yueh Shi , Huey-Chun Huang
Inventor： Hua-Lin Wu , Guey-Yueh Shi , Huey-Chun Huang
IPC: A61K31/7004 , A61K31/737 , A61K38/36 , A61K45/06 , C07K14/745 , C07K16/36 , G01N33/574 , C12Q1/68 , A61K38/48 , C12N9/74 , G01N33/53 , G01N33/567
CPC classification number: C07K16/36 , A61K31/7004 , A61K31/737 , A61K38/36 , A61K45/06 , C07K14/7455 , C07K2317/76 , G01N33/574 , A61K2300/00
Abstract: The present invention relates to compositions, kits and treating methods for the alteration cell-cell adhesion, transport, or permeation properties of tissues. The present invention also relates to the application of drug(s) or peptide(s), compound or gene delivery, DNA or RNA(i), cosmetic or therapeutic use of the compositions and kits.
Abstract translation: 本发明涉及用于改变组织的细胞 - 细胞粘附，转运或渗透性质的组合物，试剂盒和处理方法。 本发明还涉及药物或肽，化合物或基因递送，DNA或RNA（i），组合物和试剂盒的美容或治疗用途的应用。
-
公开(公告)号：US09730983B2
公开(公告)日：2017-08-15
申请号：US14873880
申请日：2015-10-02
Applicant: Chih-Yuan Ma , Guey-Yueh Shi , Hua-Lin Wu
Inventor： Chih-Yuan Ma , Guey-Yueh Shi , Hua-Lin Wu
CPC classification number: A61K38/366 , A61K9/0019
Abstract: A method for blocking, inhibiting and/or decreasing cluster of differentiation 14 (CD14) function, CD14-mediated cellular response and/or treating CD14-mediated pathological conditions is disclosed. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising: (a) a therapeutically effective amount of a recombinant protein comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1, wherein the recombinant protein does not comprises a lectin-like domain 1 of a human thrombomodulin; and (b) a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.
-
公开(公告)号：US09061000B2
公开(公告)日：2015-06-23
申请号：US13733902
申请日：2013-01-04
Applicant: Chao-Han Lai , Guey-Yueh Shi , Hua-Lin Wu
Inventor： Chao-Han Lai , Guey-Yueh Shi , Hua-Lin Wu
IPC: A61K38/36
CPC classification number: A61K38/366
Abstract: A method for pharmacological prevention and suppression of aortic aneurysm development is disclosed. The method comprises administering a therapeutically effective amount of recombinant thrombomodulin to a subject in need thereof. The recombinant thrombomodulin prevents formation and/or retards progression of an aortic aneurysm.
Abstract translation: 公开了用于药理学预防和抑制主动脉瘤发展的方法。 该方法包括向有需要的受试者施用治疗有效量的重组血栓调节素。 重组血栓调节蛋白阻止主动脉瘤的形成和/或延缓进展。
-
公开(公告)号：US07939567B2
公开(公告)日：2011-05-10
申请号：US11361589
申请日：2006-02-24
Applicant: Hua-Lin Wu , Guey-Yueh Shi
Inventor： Hua-Lin Wu , Guey-Yueh Shi
IPC: A01N33/02
CPC classification number: A61K31/485 , Y10S514/859
Abstract: The present invention relates to a method for providing bactericide or bacteriostatic, especially for treating disease due to bacterial infection. The method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of dextromethorphan or naloxone or a pharmaceutically acceptable salt or an analog thereof. The compound is applied to skin or mucosal surface of the patient. The invention also relates to a method of treating inflammation caused by suppressing secretion of TNF-α, IL-6, or MCP-1 from macrophage comprising administering a patient in need of such treatment a therapeutically effective amount of NADPH oxidase inhibitor.
Abstract translation: 本发明涉及一种提供杀菌剂或抑菌剂的方法，特别是用于治疗由细菌感染引起的疾病。 该方法包括给予需要这种治疗的患者治疗有效量的右美沙芬或纳洛酮或其药学上可接受的盐或类似物的化合物。 该化合物应用于患者的皮肤或粘膜表面。 本发明还涉及一种治疗由巨噬细胞抑制TNF-α，IL-6或MCP-1分泌引起的炎症的方法，包括给予需要这种治疗的患者治疗有效量的NADPH氧化酶抑制剂。
-
Patent Agency Ranking
6.发明授权公开(公告)号：US07820689B2
公开(公告)日：2010-10-26
申请号：US11836159
申请日：2007-08-09
Applicant: Hua-Lin Wu , Guey-Yueh Shi
Inventor： Hua-Lin Wu , Guey-Yueh Shi
CPC classification number: A61K31/485
Abstract: The present invention relates to a method for preventing or treating a cardiovascular disease.
Abstract translation: 本发明涉及一种预防或治疗心血管疾病的方法。
-
公开(公告)号：US20090118189A1
公开(公告)日：2009-05-07
申请号：US12316194
申请日：2008-12-10
Applicant: Hua-Lin Wu , Guey-Yueh Shi
Inventor： Hua-Lin Wu , Guey-Yueh Shi
IPC: A61K38/16
CPC classification number: A61K48/00 , A61K38/366
Abstract: The invention relates to a composition for promoting angiogenesis, for controlling DNA synthesis of a cell, and for controlling chemotactic motility of a cell. The invention also relates to a method for treating ischemia diseases.
Abstract translation: 本发明涉及促进血管发生的组合物，用于控制细胞的DNA合成和用于控制细胞的趋化运动性。 本发明还涉及一种治疗缺血性疾病的方法。
-
8.发明授权
公开(公告)号：US5876999A
公开(公告)日：1999-03-02
申请号：US568393
申请日：1995-12-06
Applicant: Hua-Lin Wu
Inventor： Hua-Lin Wu
CPC classification number: C07K14/3153 , A61K38/00
Abstract: Mutants of streptokinase in which one or more amino acid residues in the region of Pro58-Lys59-Ser60-Lys61 were replaced by other amino acids become better fibrinolytic agents. The mutants are resistant to the hydrolytic inactivation by plasmin and are more efficient in inducing fibrinolysis of plasma clots.
Abstract translation: 其中Pro58-Lys59-Ser60-Lys61区域中的一个或多个氨基酸残基被其它氨基酸替代的链激酶突变体变成更好的纤维蛋白溶解剂。 突变体对纤溶酶的水解失活具有抗性，并且更有效地诱导血浆凝块的纤维蛋白溶解。
-
公开(公告)号：US20210361747A1
公开(公告)日：2021-11-25
申请号：US16882508
申请日：2020-05-24
Applicant: Yi-Hsun HUANG , Hua-Lin Wu
Inventor： Yi-Hsun HUANG , Hua-Lin Wu
Abstract: The present application relates to dual anti-angiogenic and anti-inflammatory effects of recombinant thrombomodulin domain 1 (TMD1). Specifically, an isolated recombinant polypeptide comprising an amino acid sequence that is at least 80% identical to TMD1 for use in treating an eye disease and/or an eye disorder associated with pathological ocular angiogenesis (POA) in a subject in need thereof is disclosed. The length of the recombinant polypeptide is no more than 200 amino acid residues. The eye disease and/or the eye disorder may be at least one selected from the group consisting of retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. Use of TMD1 in the manufacture of a medicament for treating an eye disease and/or an eye disorder associated with vascular endothelial growth factor (VEGF)-induced ocular angiogenesis and/or hypoxia-inducible factor-1α (HIF-1α)-VEGF pathway is also disclosed.
-
公开(公告)号：US20120165244A1
公开(公告)日：2012-06-28
申请号：US13418577
申请日：2012-03-13
Applicant: Hua-Lin Wu , Guey-Yueh Shi
Inventor： Hua-Lin Wu , Guey-Yueh Shi
CPC classification number: A61K38/366
Abstract: The present invention relates to a method for binding Lewis Y antigen of a subject, comprising administering to the subject an effective amount of N-terminal lectin-like domain of thrombomodulin (TMD1), or its analogues.
Abstract translation: 本发明涉及用于结合受试者的Lewis Y抗原的方法，其包括给予受试者有效量的血栓调节蛋白（TMD1）的N-末端凝集素样结构域或其类似物。
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.019 seconds)
